Table 2.
Phase 1 (n=14) | Phase 2 (n=13) | Phase 3 (n=14) | P value | |
---|---|---|---|---|
Initial buprenorphine* dose | 2 (1) | 3 (1) | 3 (1) | <.05 (1<2,3) |
Total buprenorphine* dose at the program | 9 (6) | 7 (3) | 6 (4) | NS |
Total buprenorphine* dose, Day #1 | 13 (6) | 11 (6) | 14 (9) | NS |
Includes mean (standard deviation) buprenorphine dose in mg for both buprenorphine-naloxone combination and pure buprenorphine formulations.
NS = non-significant